Assessment of CD37 B-cell antigen and cell of origin significantly improves risk prediction in diffuse large B-cell lymphoma

Xu-Monette, Zijun Y; Li, Ling; Byrd, John C; Jabbar, Kausar J; Manyam, Ganiraju C; de Winde, Charlotte Maria; van den Brand, Michiel; Tzankov, Alexandar; Visco, Carlo; Wang, Jing; Dybkaer, Karen; Chiu, April; Orazi, Attilio; Zu, Youli; Bhagat, Govind; Richards, Kristy L; Hsi, Eric D; Choi, William WL; Huh, Jooryung; Ponzoni, Maurilio; Ferreri, Andres JM; Moller, Michael B; Parsons, Ben M; Winter, Jane N; Wang, Michael; Hagemeister, Frederick B; Piris, Miguel A; van Krieken, J Han; Medeiros, L Jeffrey; Li, Yong; van Spriel, Annemiek B; Young, Ken H

doi:10.1182/blood-2016-05715094

Type

Subject

Science & Technology
Life Sciences & Biomedicine
Hematology
NON-HODGKINS-LYMPHOMA
CLASS-II EXPRESSION
PROGNOSTIC-SIGNIFICANCE
THERAPEUTIC PROTEIN
GENE-EXPRESSION
POOR-PROGNOSIS
CD20 LEVELS
RITUXIMAB
TETRASPANINS
MECHANISMS

Permalink

https://hdl.handle.net/10161/19332

Published Version (Please cite this version)

10.1182/blood-2016-05715094

Publication Info

Xu-Monette, Zijun Y; Li, Ling; Byrd, John C; Jabbar, Kausar J; Manyam, Ganiraju C; de Winde, Charlotte Maria; ... Young, Ken H (2016). Assessment of CD37 B-cell antigen and cell of origin significantly improves risk prediction in diffuse large B-cell lymphoma. BLOOD, 128(26). pp. 3083-3100. 10.1182/blood-2016-05715094. Retrieved from https://hdl.handle.net/10161/19332.

This is constructed from limited available data and may be imprecise. To cite this article, please review & use the official citation provided by the journal.

Collections

Scholarly Articles

More Info

Show full item record

Scholars@Duke

Zijun Yidan Xu-Monette

Assistant Professor in Pathology

My research efforts have been focused on identifying prognostic and therapeutic biomarkers in B-cell lymphoma. My research interests also include investigation of molecular and immune mechanisms underlying the poor clinical outcomes of lymphoma, the pathogenesis and evolution of drug resistant clones, and development of novel therapies for aggressive B-cell lymphoma.

Ken H Young

Professor of Pathology

I am a clinically-oriented diagnostic physician with clinical expertise in the pathologic diagnosis of hematologic cancers including tumors of the bone marrow, lymphoid tissue, spleen and pre-malignant hematologic conditions. Another area of interest is blood cancer classification with molecular and genetic profiling. In my research program, we focus on molecular mechanisms of tumor progression, cell-of-origin, biomarkers, and novel therapeutic strategies in lymphoma, myeloma and leukemia. In

Alphabetical list of authors with Scholars@Duke profiles.

Articles written by Duke faculty are made available through the campus open access policy. For more information see: Duke Open Access Policy

Rights for Collection: Scholarly Articles

Works are deposited here by their authors, and represent their research and opinions, not that of Duke University. Some materials and descriptions may include offensive content. More info